Table 1.
Baseline characteristics of men with a first benign prostatic hyperplasia (BPH) diagnosis, defined as either a hospital-based diagnosis, transurethral resection of the prostate, or a BPH related prescription in Denmark in 1996–2016 and men in the comparison cohort who were alive and started follow-up, one year after the BPH diagnosis/index date.
| Men with BPH n = 297 026 N (%) | Comparison cohort n = 1 107 176 N (%) | |
|---|---|---|
| Age groups, years | ||
| <60 | 76 434 (25·7) | 301 002 (27·2) |
| 60–69 | 92 960 (31·3) | 356 549 (32·2) |
| 70–79 | 86 583 (29·1) | 315 891 (28·5) |
| 80+ | 41 049 (13·8) | 133 734 (12·1) |
| Education | ||
| Primary school (≤9 years) | 93 730 (31·6) | 363 633 (32·8) |
| Secondary/vocational (10–12 years) | 110 921 (37·3) | 423 134 (38·2) |
| Higher education (>12 years) | 57 074 (19·2) | 201 718 (18·2) |
| Missing | 35 301 (11·9) | 118,691 (10·7) |
| Employment | ||
| Employed/self-employed | 110 188 (37·1) | 446 889 (40·4) |
| Unemployed | 9653 (3·2) | 35 693 (3·2) |
| Early retirement pensioner | 39 941 (13·4) | 135 691(12·3) |
| Retired | 136 012 (45·8) | 480 223 (43·4) |
| Missing | 1232 (0·4) | 8680 (0·8) |
| Income | ||
| Low (1st quartile) | 71 195 (24·0) | 260 619 (23·5) |
| Medium-low (2nd quartile) | 72 181 (24·3) | 265 316 (24·0) |
| Medium-high (3rd quartile) | 74 477 (25·1) | 279 183 (25·2) |
| High (4th quartile) | 78 631 (26·5) | 298 373 (26·9) |
| Missing | 542 (0·2) | 3685 (0·3) |
| Calendar period of BPH diagnosis/index date | ||
| 1996–2002 | 109 844 (37·0) | 402 952 (36·4) |
| 2003–2009 | 97 017 (32·7) | 362 960 (32·8) |
| 2010–2016 | 90 165 (30·4) | 341 264 (30·8) |
| Comorbidities at baseline | ||
| Cardiovascular disease | 63 431 (21·4) | 195 700 (17·7) |
| Stroke | 17 069 (5·7) | 47 579 (4·3) |
| Diabetes mellitus | 19 964 (6·7) | 54 720 (4·9) |
| Hyperlipidemia / hypercholesterolemia | 17 009 (5·7) | 49 377 (4·5) |
| Hypertension | 43 511 (14·6) | 111 223 (10·0) |
| Obesity | 7085 (2·4) | 17 488 (1·6) |
| Chronic obstructive pulmonary disease | 21 809 (7·3) | 60 033 (5·4) |
| Renal failure | 4188 (1·4) | 6436 (0·6) |
| Prostate cancer | 6675 (2·2) | 11 539 (1·0) |
| Use of medication at or before baseline | ||
| NSAIDs* | 54 648 (18·4) | 139 718 (12·6) |
| Testosterone | 1699 (0·6) | 4052 (0·4) |
| Follow-up, years | ||
| Median, interquartile range | 6·9 (3·6–11·6) | 6·4 (3·4–10·8) |
| Events during follow up | ||
| Transurethral resection of the prostate** | 49 418 (16·6) | – |
| Renal failure | 16 854 (5·7) | 32 952 (3·0) |
| Prostate cancer | 29 453 (9·9) | 31 506 (2·8) |
*within 6 months before index date **within 5 years before or after index date.